Founded in 2009, Cytosurge AG develops, manufactures and distributes based on its patented FluidFM® technology state-of-the-art nanotechnology solutions, such as the FluidFM BOT for single cell research and FluidFM ADD-ONs for selected Atomic Force Microscopes (AFMs) and the FluidFM µ3Dprinter for 3D metal printing at the micrometer scale. The hollow FluidFM probes have apertures as small as 300 nm enabling more than distinctive 12 applications such as single cell adhesion measurements, nano-injection, nano-extraction and nano-printing.
The FluidFM BOT is a highly automated stand-alone system for cell research: Proteins, CRISPR-Cas complexes, RNAs or plasmids can be injected in a non-destructive and measurable manner directly selectively into the nucleus or cytoplasm of adherent cells. Combining nano-injection with other applications, such as cell isolation and nano-printing, enables the design of new research approaches, for example building neural networks.
FluidFM - GO BEYOND.
- Founding year: 2009
- Employee count (Apr. 2019): 11-50
Your web browser is outdated. Update your browser for more security, speed and optimal presentation of this page.Update Browser